Skip to main content

Advertisement

Log in

The methamphetamine epidemic: Implications for HIV prevention and treatment

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Methamphetamine and related amphetamine compounds are among the most commonly used illicit drugs, with over 35 million users worldwide. In the United States, admissions for methamphetamine treatment have increased dramatically over the past 10 years. Methamphetamine use is prevalent among persons with HIV infection and persons at risk for HIV, particularly among men who have sex with men. In addition to being associated with increased sexual risk behavior, methamphetamine causes significant medical morbidity, including neurologic deficits, cardiovascular compromise, dental decay, and skin infections, all of which may be worsened in the presence of HIV/AIDS. Methamphetamine use may also result in decreased medication adherence, particularly during "binging" episodes. Behavioral counseling remains the standard of treatment for methamphetamine dependence, although the effectiveness of most counseling interventions has not been rigorously tested. Pharmacologic and structural interventions may prove valuable additional interventions to reduce methamphetamine use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cretzmeyer M, Sarrazin MV, Huber DL, et al.: Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 2003, 24:267–277.

    Article  PubMed  Google Scholar 

  2. Rawson RA, Anglin MD, Ling W: Will the methamphetamine problem go away? J Addict Dis 2002, 21:5–19.

    Article  PubMed  Google Scholar 

  3. Ellinwood EH, King G, Lee TH: Chronic amphetamine use and abuse. In Psychopharmacology: The Fourth Generation of Progress CD-ROM. Edited by Watson SJ. Philadelphia, PA: Lippincott, Williams & Wilkins; 1998.

    Google Scholar 

  4. Suo S: Unnecessary epidemic. The Oregonian, October 3–7, 2004:1–24. Excellent overview of the methamphetamine epidemic.

  5. National Institute on Drug Abuse: InfoFacts: Nationwide trends: NIDA, http://www.drugabuse.gov/Infofax/nationtrends.html.2004.

  6. Methamphetamine treatment admission rates higher than those of cocaine and/or heroin in western states. CESAR Fax 2005, 14:12.

  7. Substance Abuse and Mental Health Services Administration: 2003 National survey on drug use and health. http://oas.samhsa.gov/NHSDA/2k3NSDUH/2k3results.htm.

  8. Cho AK, Melega WP: Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002, 21:21–34.

    Article  PubMed  Google Scholar 

  9. Colfax G, Vittinghoff E, Husnik MJ, et al.: Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol 2004, 159:1002–1012.

    Article  PubMed  Google Scholar 

  10. Stall R, Paul JP, Greenwood G, et al.: Alcohol use, drug use, and alcohol-related problems among men who have sex with men: the Urban Health Study. Addiction 2001, 96:1589–1601.

    Article  PubMed  CAS  Google Scholar 

  11. Thiede H, Valleroy LA, MacKellar DA, et al.: Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas. Am J Public Health 2003, 93:1915–1921.

    PubMed  Google Scholar 

  12. Colfax GN, Mansergh G, Guzman R, et al.: Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001, 28:373–379.

    PubMed  CAS  Google Scholar 

  13. Mitchell SJ, Wong W, Kent CK, et al.: Methamphetamine use and sexual activity among HIV-infected patients in care—San Francisco, 2004. Paper presented at National HIV Prevention Conference, Atlanta, GA; June 13–15, 2005.

  14. RawsonRA, Gonzales R, Brethen P: Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 2002, 23:145–150. An important review of treatment options.

    Article  PubMed  Google Scholar 

  15. NordahlTE, Salo R, Leamon M: Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003, 15:317–325. An excellent review of the neurologic consequences of methamphetamine.

    PubMed  CAS  Google Scholar 

  16. McCann UD, Ricaurte GA: Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 2004, 27:821–826.

    Article  PubMed  CAS  Google Scholar 

  17. Johnson M, Stone DM, Hanson GR, et al.: Role of the dopaminergic nigrostriatal pathway in methamphetamine-induced depression of the neostriatal serotonergic system. Eur J Pharmacol 1987, 135:231–234.

    Article  PubMed  CAS  Google Scholar 

  18. Mark KA, Soghomonian JJ, Yamamoto BK: High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 2004, 24:11449–11456.

    Article  PubMed  CAS  Google Scholar 

  19. Sekine Y, Iyo M, Ouchi Y, et al.: Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001, 158:1206–1214.

    Article  PubMed  CAS  Google Scholar 

  20. London ED, Simon SL, Berman SM, et al.: Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 2004, 61:73–84.

    Article  PubMed  Google Scholar 

  21. Volkow ND, Chang L, Wang GJ, et al.: Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry 2001, 158:383–389.

    Article  PubMed  CAS  Google Scholar 

  22. Simon SL, Domier C, Carnell J, et al.: Cognitive impairment in individuals currently using methamphetamine. Am J Addict 2000, 9:222–231.

    Article  PubMed  CAS  Google Scholar 

  23. Ornstein TJ, Iddon JL, Baldacchino AM, et al.: Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23:113–126.

    Article  PubMed  CAS  Google Scholar 

  24. Peck JA, Reback CJ, Yang X, et al.: Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 2005, 82:i100–108.

    PubMed  Google Scholar 

  25. Nordahl TE, Salo R, Natsuaki Y, et al.: Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2005, 62:444–452.

    Article  PubMed  Google Scholar 

  26. Hardman JG, Limbird L, Gilman AG, eds.: The Pharmacologic Basis of Therapeutics. New York: McGrawHill, 2001.

    Google Scholar 

  27. Lee NE, Taylor MM, Bancroft E, et al.: Risk factors for community -associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005, 40:1529–1534.

    Article  PubMed  Google Scholar 

  28. McGrath C, Chan B: Oral health sensations associated with illicit drug abuse. Br Dent J 2005, 198:159–162.

    Article  PubMed  CAS  Google Scholar 

  29. Buffum JC, Shulgin AT: Overdose of 2.3 grams of intravenous methamphetamine: case, analysis and patient perspective. J Psychoactive Drugs 2001, 33:409–412.

    PubMed  CAS  Google Scholar 

  30. Lan KC, Lin YF, Yu FC, et al.: Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 1998, 97:528–533.

    PubMed  CAS  Google Scholar 

  31. Perez JA, Jr, Arsura EL, Strategos S: Methamphetamine-related stroke: four cases. J Emerg Med 1999, 17:469–471.

    Article  PubMed  Google Scholar 

  32. Hong R, Matsuyama E, Nur K: Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991, 265:1152–1154.

    Article  PubMed  CAS  Google Scholar 

  33. Reback CJ, Larkins S, Shoptaw S: Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS Behav 2004, 8:87–98.

    Article  PubMed  Google Scholar 

  34. Ling W, Shoptaw S, Majewska D: Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 1998, 18:403–404.

    Article  PubMed  CAS  Google Scholar 

  35. Semple SJ, Patterson TL, Grant I: Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat 2002, 22:149–156.

    Article  PubMed  Google Scholar 

  36. Shoptaw S, Tross S, Stephens MA, et al.: A snapshot of HIV-related assessment and treatment services at participating clinical treatment providers in NIDA’s clinical trials network. Paper presented at XIV International AIDS Conference. Barcelona, Spain; July 7–12, 2002.

  37. Molitor F, Truax SR, Ruiz JD,et al.: Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 1998, 168:93–97.

    PubMed  CAS  Google Scholar 

  38. Mansergh G, Colfax GN, Marks G, et al.: The Circuit Party Men’s Health Survey: findings and implications for gay and bisexual men. Am J Public Health 2001, 91:953–958.

    Article  PubMed  CAS  Google Scholar 

  39. Paul JP, Stall R, Davis F: Sexual risk for HIV transmission among gay/bisexual men in substance-abuse treatment. AIDS Educ Prev 1993, 5:11–24.

    PubMed  CAS  Google Scholar 

  40. Myers T, Rowe CJ, Tudiver FG, et al.: HIV, substance use and related behavior of gay and bisexual men: an examination of the Talking Sex project cohort. Br J Addict 1992, 87:207–214.

    Article  PubMed  CAS  Google Scholar 

  41. Paul JP, Stall RD, Crosby GM, et al.: Correlates of sexual risk-taking among gay male substance abusers. Addiction 1994, 89:971–983.

    Article  PubMed  CAS  Google Scholar 

  42. Wong W, Chaw JK, Kent CK, et al.: Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002–2003. Sex Transm Dis 2005, 32:458–463.

    Article  PubMed  Google Scholar 

  43. Buchacz K, McFarland W, Kellog T, et al.: Amphetamine use is associated with increased HIV incidence among men who have sex with men (MSM) in San Francisco. AIDS 2005, In press.

  44. Rawson RA, Huber A, Brethen P, et al.: Status of methamphetamine users 2–5 years after outpatient treatment. J Addict Dis 2002, 21:107–119.

    Article  PubMed  Google Scholar 

  45. Molitor F, Ruiz JD, Flynn N, et al.: Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. Am J Drug Alcohol Abuse 1999, 25:475–493.

    Article  PubMed  CAS  Google Scholar 

  46. Halkitis PN, Parsons JT, Stirratt MJ: A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex 2001, 41:17–35.

    Article  PubMed  CAS  Google Scholar 

  47. Stone E, Heagerty P, Vittinghoff E, et al.: Correlates of condom failure in a sexually active cohort of men who have sex with men. J Acquir Immune Defic SyndrHum Retrovirol 1999, 20:495–501.

    CAS  Google Scholar 

  48. Wohl AR, Johnson DF, Lu S, et al.: HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr 2002, 31:354–360.

    PubMed  Google Scholar 

  49. Semple SJ, Grant I, Patterson TL: Female methamphetamine users: social characteristics and sexual risk behavior. Women Health 2004, 40:35–50.

    Article  PubMed  Google Scholar 

  50. Bogart LM, Kral AH, Scott A, et al.: Sexual risk among injection drug users recruited from syringe exchange programs in California. Sex Transm Dis 2005, 32:27–34.

    Article  PubMed  Google Scholar 

  51. Ellis RJ, Childers ME, Cherner M, et al.: Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003, 188:1820–1826.

    Article  PubMed  Google Scholar 

  52. Gavrilin MA, Mathes LE, Podell M: Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 2002, 8:240–249.

    Article  PubMed  CAS  Google Scholar 

  53. Rippeth JD, Heaton RK, Carey CL, et al.: Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 2004, 10:1–14.

    Article  PubMed  CAS  Google Scholar 

  54. Langford D, Adame A, Grigorian A, et al.: Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 2003, 34:467–474.

    Article  PubMed  CAS  Google Scholar 

  55. Urbina A, Jones K: Crystal methamphetamine, its analogues, and HIV-infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 2004, 38:890–894.

    Article  PubMed  Google Scholar 

  56. Henry JA, Hill IR: Fatal interaction between ritonavir and MDMA. Lancet 1998, 352:1751–1752.

    Article  PubMed  CAS  Google Scholar 

  57. Hales G, Roth N, Smith D: Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther 2000, 5:19.

    PubMed  CAS  Google Scholar 

  58. Reback CJ, Larkins S, Shoptaw S: Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 2003, 15:775–785.

    Article  PubMed  CAS  Google Scholar 

  59. Gorman M, Halkitis P: Methamphetamine and club drug use and HIV. Focus 2003, 18:5–6.

    PubMed  Google Scholar 

  60. Rawson RA, Simon SL, Ling W: If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic? J Addict Dis 2002, 21:1–4.

    Article  PubMed  Google Scholar 

  61. Maglione M, Chao B, Anglin MD: Correlates of outpatient drug treatment drop-out among methamphetamine users. J Psychoactive Drugs 2000, 32:221–228.

    PubMed  CAS  Google Scholar 

  62. Stall RD, Paul JP, Barrett DC, et al.: An outcome evaluation to measure changes in sexual risk-taking among gay men undergoing substance use disorder treatment. J Stud Alcohol 1999, 60:837–845.

    PubMed  CAS  Google Scholar 

  63. Rawson RA, Marinelli-Casey P, Anglin MD, et al.: A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004, 99:708–717. Results of an important randomized trial for methamphetamine dependence.

    Article  PubMed  Google Scholar 

  64. Tweaker.org. http://www.tweaker.org/. Accessed July 2005.

  65. Higgins ST, Budney AJ, Bickel WK, et al.: Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993, 150:763–769.

    PubMed  CAS  Google Scholar 

  66. Iguchi MY, Stitzer ML, Bigelow GE, et al.: Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend 1988, 22:1–7.

    Article  PubMed  CAS  Google Scholar 

  67. Shoptaw S, Reback CJ, Peck JA, et al.: Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend 2005, 78:125–134.

    Article  PubMed  Google Scholar 

  68. Shearer J, Wodak A, Mattick RP, et al.: Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001, 96:1289–1296.

    Article  PubMed  CAS  Google Scholar 

  69. Grabowski J, Rhoades H, Stotts A, et al.: Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004, 29:969–981.

    Article  PubMed  CAS  Google Scholar 

  70. Brodie JD, Figueroa E, Laska EM, et al.: Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005, 55:122–125.

    Article  PubMed  CAS  Google Scholar 

  71. McTavish SF, McPherson MH, Harmer CJ, et al.: Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 2001, 179:356–360.

    Article  PubMed  CAS  Google Scholar 

  72. Batki SL, Delucchi K, Hersh D, et al.: Amolodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis. Drug Alcohol Depend 2001, 63:12.

    Google Scholar 

  73. Batki SL, Moon J, Delucchi K, et al.: Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann N Y Acad Sci 2000, 909:260–263.

    Article  PubMed  CAS  Google Scholar 

  74. Galloway GP, Newmeyer J, Knapp T, et al.: A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996, 13:493–497.

    Article  PubMed  CAS  Google Scholar 

  75. Johnson BA, Rawson R, Elkashef A, et al.: Ondansetron for the treatment of methamphetamine dependence. Paper presented at Sixty-sixth Annual Scientific Meeting of College on Problems of Drug Dependence. San Juan, Puerto Rico; June 12–17, 2004.

  76. Cunningham JK, Liu LM: Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 2005, 100:479–488.

    Article  PubMed  Google Scholar 

  77. Cunningham JK, Liu LM: Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 2003, 98:1229–1237.

    Article  PubMed  Google Scholar 

  78. Centers for Disease Control and Prevention: Revised guidelines for HIV counseling, testing, and referral. MMWR 2001, 50:1–58.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colfax, G., Shoptaw, S. The methamphetamine epidemic: Implications for HIV prevention and treatment. Curr HIV/AIDS Rep 2, 194–199 (2005). https://doi.org/10.1007/s11904-005-0016-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-005-0016-4

Keywords

Navigation